Latest News
Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing
AveXis, a Novartis company, announced a one-time infusion of Zolgensma® (onasemnogene abeparvovec-xioi) showed rapid, significant, and clinically meaningful therapeutic benefit in patients with spinal muscular atrophy (SMA) across a range […]
Read More ›Community Spotlight: Raising Money for Cure SMA, One Cookie at a Time
Dana Perella is a 9-year-old on a mission to raise $50,000 for spinal muscular atrophy (SMA) research in 2020. She began baking cookies to raise money for her friend Mila, […]
Read More ›Cure SMA Launches Part 2 of “Spotlight on SMA” in Partnership with Neurology Reviews
Cure SMA is pleased to announce the release of “Spotlight on SMA: The Spinal Muscular Atrophy Treatment Landscape,” the final supplement in a two-part series developed in collaboration with Neurology […]
Read More ›Cure SMA Announces Additional Event Cancellations; No Changes to Plans and Recommendations for Annual SMA Conference
As news about the Coronavirus (COVID-19) continues to evolve, Cure SMA has now decided to cancel all events (i.e., galas, dinners, Walk-n-Rolls, Summits of Strength) through the end of May. […]
Read More ›2020 Annual SMA Conference Schedule is Released
Cure SMA has released the schedule for the 2020 Annual SMA Conference, which will be held at Disney’s Yacht & Beach Club Resorts in Orlando, Fla., from Thursday, June 11th thru […]
Read More ›Grant Announcement: Cure SMA Awards $150,000 Grant to Emily Welby, Ph.D., Medical College of Wisconsin
This article is part of a series of Cure SMA grant announcements being shared throughout the winter/spring. Cure SMA has awarded a $150,000 grant to Emily Welby, Ph.D., of the […]
Read More ›